See more : ÖKOWORLD AG (VVV3.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Sight Sciences, Inc. (SGHT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sight Sciences, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Topre Corporation (5975.T) Income Statement Analysis – Financial Results
- Enbridge Inc. (0KTI.L) Income Statement Analysis – Financial Results
- ANAP Inc. (3189.T) Income Statement Analysis – Financial Results
- PT Semen Indonesia (Persero) Tbk (PSGTF) Income Statement Analysis – Financial Results
- Slate Grocery REIT (SGR-UN.TO) Income Statement Analysis – Financial Results
Sight Sciences, Inc. (SGHT)
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 81.06M | 71.33M | 48.96M | 27.64M | 23.35M | 7.53M |
| Cost of Revenue | 11.88M | 12.36M | 8.61M | 9.21M | 6.54M | 2.34M |
| Gross Profit | 69.18M | 58.97M | 40.35M | 18.43M | 16.80M | 5.19M |
| Gross Profit Ratio | 85.34% | 82.67% | 82.41% | 66.68% | 71.97% | 68.95% |
| Research & Development | 17.56M | 22.86M | 15.63M | 8.87M | 8.12M | 5.43M |
| General & Administrative | 106.79M | 117.47M | 74.09M | 40.95M | 30.92M | 13.06M |
| Selling & Marketing | 2.10M | 2.60M | 2.10M | 800.00K | 1.80M | 1.00M |
| SG&A | 108.89M | 120.07M | 76.19M | 41.75M | 32.72M | 14.06M |
| Other Expenses | 0.00 | 2.23M | -6.93M | -71.00K | -35.00K | 0.00 |
| Operating Expenses | 126.45M | 142.92M | 91.82M | 50.62M | 40.84M | 19.49M |
| Cost & Expenses | 138.33M | 155.29M | 100.43M | 59.83M | 47.39M | 21.83M |
| Interest Income | 0.00 | 4.47M | 4.37M | 30.00K | 174.00K | 1.00K |
| Interest Expense | 5.41M | 4.47M | 4.37M | 2.40M | 1.96M | 0.00 |
| Depreciation & Amortization | 614.00K | 1.25M | 1.20M | 1.12M | 432.00K | 63.00K |
| EBITDA | -49.42M | -80.48M | -57.21M | -31.68M | -23.47M | -14.23M |
| EBITDA Ratio | -60.96% | -114.58% | -119.30% | -114.60% | -101.10% | -189.02% |
| Operating Income | -57.27M | -83.95M | -51.48M | -32.19M | -24.04M | -14.30M |
| Operating Income Ratio | -70.66% | -117.70% | -105.15% | -116.45% | -102.96% | -189.87% |
| Total Other Income/Expenses | 1.84M | -2.24M | -11.29M | -2.44M | -1.82M | 1.00K |
| Income Before Tax | -55.44M | -86.20M | -62.77M | -34.63M | -25.86M | -14.30M |
| Income Before Tax Ratio | -68.39% | -120.84% | -128.22% | -125.30% | -110.76% | -189.85% |
| Income Tax Expense | 110.00K | 47.00K | 188.00K | 61.00K | 8.00K | -6.00K |
| Net Income | -55.55M | -86.24M | -62.96M | -34.69M | -25.87M | -14.29M |
| Net Income Ratio | -68.53% | -120.90% | -128.61% | -125.52% | -110.80% | -189.77% |
| EPS | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| EPS Diluted | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| Weighted Avg Shares Out | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
| Weighted Avg Shares Out (Dil) | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. Patients...
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. The analysis published in Clinical Ophthalmology suggests that OMNI was...
Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link...
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago.
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial...
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a...
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it...
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyes The efficacy of the three most commonly used MIGS technologies in...
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease.
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today...
Source: https://incomestatements.info
Category: Stock Reports